These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9453072)

  • 1. Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.
    van der Geest R; van Laar T; Gubbens-Stibbe JM; Boddé HE; Danhof M
    Pharm Res; 1997 Dec; 14(12):1804-10. PubMed ID: 9453072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.
    Junginger HE
    Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S57-75. PubMed ID: 12460716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iontophoretic delivery of apomorphine. I: In vitro optimization and validation.
    van der Geest R; Danhof M; Boddé HE
    Pharm Res; 1997 Dec; 14(12):1798-803. PubMed ID: 9453071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment.
    Li GL; de Vries JJ; van Steeg TJ; van den Bussche H; Maas HJ; Reeuwijk HJ; Danhof M; Bouwstra JA; van Laar T
    J Control Release; 2005 Jan; 101(1-3):199-208. PubMed ID: 15588905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies.
    Li GL; Grossklaus A; Danhof M; Bouwstra JA
    Int J Pharm; 2003 Nov; 266(1-2):61-8. PubMed ID: 14559394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
    van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
    Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
    van der Geest R; van Laar T; Kruger PP; Gubbens-Stibbe JM; Boddé HE; Roos RA; Danhof M
    Clin Neuropharmacol; 1998; 21(3):159-68. PubMed ID: 9617507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
    Sam E; Jeanjean AP; Maloteaux JM; Verbeke N
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):27-33. PubMed ID: 7588990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro.
    Li GL; Danhof M; Frederik PM; Bouwstra JA
    Pharm Res; 2003 Apr; 20(4):653-9. PubMed ID: 12739775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of apomorphine in Parkinson's disease.
    Gancher S
    J Neural Transm Suppl; 1995; 45():137-41. PubMed ID: 8748619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lontophoretic delivery of apomorphine in vitro: physicochemic considerations.
    Li GL; Danhof M; Bouwstra JA
    Pharm Res; 2001 Nov; 18(11):1509-13. PubMed ID: 11758756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and testing of a new iontophoretic continuous flow through transport cell.
    van der Geest R; Danhof M; Boddé HE
    J Control Release; 1998 Jan; 51(1):85-91. PubMed ID: 9685906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease.
    Boddé HE; Van Laar T ; Van der Geest R ; Danhof M
    Adv Drug Deliv Rev; 1998 Sep; 33(3):253-263. PubMed ID: 10837665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled iontophoretic delivery of pramipexole: electrotransport kinetics in vitro and in vivo.
    Kalaria DR; Patel P; Merino V; Patravale VB; Kalia YN
    Eur J Pharm Biopharm; 2014 Sep; 88(1):56-63. PubMed ID: 24525072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
    LeWitt PA
    Neurology; 2004 Mar; 62(6 Suppl 4):S8-11. PubMed ID: 15037665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application.
    Nugroho AK; Della-Pasqua O; Danhof M; Bouwstra JA
    Pharm Res; 2005 Mar; 22(3):335-46. PubMed ID: 15835738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.
    Nugroho AK; Li GL; Danhof M; Bouwstra JA
    Pharm Res; 2004 May; 21(5):844-50. PubMed ID: 15180344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.